Existing drug alleviates symptoms of a rare genetic syndrome

FHS
May 30, 2024
7:15 pm

A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1).

Opinion | Flipping Panel Management on Its Head

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

October 1, 2024

PharmaDrug’s Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – October 31, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on

October 31, 2024

F2G plans resubmission after FDA rejects Olorofim NDA – Pharmaceutical Technology

F2G’s Olorofim is intended to treat rare fungal infections such as azole-resistant aspergillosis, scedosporiosis and lomentosporiosis Source: Shutterstock / Kateryna Kon. UK-based biotech F2G was

June 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.